Abeona Therapeutics Inc
NASDAQ:ABEO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abeona Therapeutics Inc
Interest Income Expense
Abeona Therapeutics Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abeona Therapeutics Inc
NASDAQ:ABEO
|
Interest Income Expense
$1.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$2.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$224m
|
CAGR 3-Years
48%
|
CAGR 5-Years
39%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$732m
|
CAGR 3-Years
20%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$466.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
Abeona Therapeutics Inc
Glance View
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in New York City, New York and currently employs 90 full-time employees. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.
See Also
What is Abeona Therapeutics Inc's Interest Income Expense?
Interest Income Expense
1.8m
USD
Based on the financial report for Dec 31, 2025, Abeona Therapeutics Inc's Interest Income Expense amounts to 1.8m USD.
What is Abeona Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-8%
Over the last year, the Interest Income Expense growth was 4 679%.
